Prosecution Insights
Last updated: April 19, 2026
Application No. 18/115,895

COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS

Non-Final OA §102
Filed
Mar 01, 2023
Examiner
NOTTINGHAM, KYLE GREGORY
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Gilead Sciences Inc.
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
3y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allow Rate
57 granted / 93 resolved
+1.3% vs TC avg
Strong +38% interview lift
Without
With
+37.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
44 currently pending
Career history
137
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
32.5%
-7.5% vs TC avg
§102
17.8%
-22.2% vs TC avg
§112
25.7%
-14.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 93 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 1-2, 6, 8, 16, 20, 41, 44-46, 49, 64, 69, 71-72, 74, 81, 85, 88, 92-94, 106, 109-110, 115, 134-135, 137, 139, 144, 146, 148, 155-158, 161, and 199-200 are pending. Priority Instant application 18/115,895, filed 03/01/2023 claims priority as follows: PNG media_image1.png 86 661 media_image1.png Greyscale Information Disclosure Statement All references from IDS(s) received 07/11/2023, 02/22/2024, 01/09/2025, and 11/19/2025 have been considered unless marked with a strikethrough. Election/Restrictions Applicant’s election without traverse of Group I, claims 1-2, 6, 8, 16, 20, 41, 44-46, 49, 64, 69, 71-72, 74, 81, 85, 88, 92-94, 106, 109-110, 115, 134-135, 137, 139, 144, 146, 148, 155-158, and 199 in the reply filed on 11/19/2025 is acknowledged. Applicant’s election without traverse of the species compound 5 is also acknowledged. Examination will begin with the elected species. In accordance with MPEP 803.02, if upon examination of the elected species, no prior art is found that would anticipate or render obvious the instant invention based on the elected species, the search of the Markush-type claim will be extended. If prior art is then found that anticipates or renders obvious the non-elected species, the Markush-type claim will be rejected. It should be noted that the prior art search will not be extended unnecessarily to cover all non-elected species. Should Applicant overcome the rejection by amending the claim, the amended claim will be examined again. The prior art search will be extended to the extent necessary to determine patentability of the Markush-type claim. In the event prior art is found during further examination that renders obvious or anticipates the amended Markush-type claim, the claim will be rejected and the action made final. The elected species (compound 5) was searched and applicable prior art was not identified. The search was therefore extended, in order of the compounds listed in claim 157, to compound 6: PNG media_image2.png 146 424 media_image2.png Greyscale and applicable prior art was not identified. The search was therefore extended again to compound 7: PNG media_image3.png 196 423 media_image3.png Greyscale and applicable prior art was identified. The search was not extended unnecessarily to cover all non-elected species. Claims 71, 72, 74, 81, 85, 88, 92, 106, 109, 110, 134, 146, 148, 155, 157, and 199 read on Compound 7. Therefore, claims 1–2, 6, 8, 16, 20, 41, 44–46, 49, 64, 69, 93-94, 115, 135, 137, 139, 144, 156, 158, 161, and 200 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention and/or species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 11/19/2025. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 71, 72, 74, 81, 85, 88, 92, 106, 109, 110, 134, 146, 148, 155, 157, and 199 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Zhang et al. (WO2022142477A1; filed 15 September 2021). Zhang discloses (Page 40) the compound ATV002 having the structure: PNG media_image4.png 248 231 media_image4.png Greyscale . The above compound is Compound 7 recited in present claim 157 and anticipates instant claims 71, 72, 74, 81, 85, 88, 92, 106, 109, 110, 134, 146, 148, 155, and 157. With respect to claim 199, Zhang discloses a pharmaceutical composition comprising ATV002 and a pharmaceutically acceptable carrier in paras. [00214]-[00215], which discloses adding ATV002 to HEK293T cells in an aqueous (DMEM) medium. Therefore Zhang anticipates claim 199. Conclusion Claims 71, 72, 74, 81, 85, 88, 92, 106, 109, 110, 134, 146, 148, 155, 157, and 199 are rejected. Claims 1–2, 6, 8, 16, 20, 41, 44–46, 49, 64, 69, 93-94, 115, 135, 137, 139, 144, 156, 158, 161, and 200 are withdrawn. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kyle Nottingham whose telephone number is (571)270-0640. The examiner can normally be reached M-F from 10:00 am - 6:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at (571) 270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /K.N./Examiner, Art Unit 1621 /CLINTON A BROOKS/Supervisory Patent Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Mar 01, 2023
Application Filed
Jan 09, 2026
Non-Final Rejection — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589082
COMPOSITIONS COMPRISING THYMOQUINONE AND ADDITIONAL BIOLOGICALLY ACTIVE COMPOUNDS
2y 5m to grant Granted Mar 31, 2026
Patent 12583867
PYRIDONE DERIVATIVE CRYSTAL FORM AND PREPARATION METHOD AND APPLICATION THEREFOR
2y 5m to grant Granted Mar 24, 2026
Patent 12576122
Combination Therapy for Cancer
2y 5m to grant Granted Mar 17, 2026
Patent 12564594
PHARMACEUTICAL COMPOSITION CONTAINING 9-ETHYL-6, 6-DIMETHYL-8-(4-MORPHOLIN-4-YL-PIPERIDIN-1-YL)-11-OXO-6, 11-DIHYDRO-5H-BENZO[B]CARBAZOLE-3-CARBONITRILE
2y 5m to grant Granted Mar 03, 2026
Patent 12564599
PHARMACEUTICAL COMPOSITION COMPRISING TETRAHYDROCANNABIVARIN FOR THE PREVENTION AND TREATMENT OF OVERWEIGHT
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
99%
With Interview (+37.7%)
3y 3m
Median Time to Grant
Low
PTA Risk
Based on 93 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month